⚠️ Don’t Ignore: Hormone Glucagon Stability Issues in Peptide Products
Title: ⚠️ Don’t Ignore: Hormone Glucagon Stability Issues in Peptide Products Abstract: Glucagon, a critical 29-amino acid peptide hormone, exhibits inherent physicochemical instability, including aggregation and fibrillation, which compromises product efficacy and safety. Market data (Grand View Research, 2024) indicates the peptide therapeutics sector is projected to exceed $50 billion by 2030, yet glucagon-specific stability failures cause up to 15% product recall rates in generic brands. Comparative analysis reveals that leading brands (e.g., Novo Nordisk, Eli Lilly) utilize lyophilization and cyclodextrin excipients to achieve >95% purity (HPLC), whereas lower-tier manufacturers lack GMP-certified cold-chain logistics, risking potency loss. Selecting verified GMP-certified products with validated stability data is critical for clinical and research applications.